From January 15 to 17, 2026, the 9th Annual Scientific Congress of the Saudi Interventional Radiology Society (SIRS) was held in Riyadh, the capital of Saudi Arabia. Top experts and scholars in the field of interventional radiology from around the world gathered for this prestigious event. As a National Key Clinical Specialty (Oncology) hospital and a modern international cancer specialty hospital, Guangzhou Fuda Cancer Hospital was invited to attend. Director Liu Shupeng, a medical expert, and Tan Cuicui, Head of International Affairs, represented the hospital at the congress.
At the meeting, Director Liu delivered a keynote speech entitled “The Role of Cryoablation Combined with PD-1 Inhibitors and Chemotherapy in the Treatment of Advanced Lung Cancer.” He pointed out that lung cancer remains a major global health challenge, with non-small cell lung cancer accounting for approximately 85% of all cases. Although targeted therapies such as EGFR and ALK inhibitors have significantly improved patient survival, 60%–70% of patients still develop drug resistance within 9–18 months of treatment, which has become a critical bottleneck in clinical practice.
Emerging treatment approaches, including cryoablation (which induces immunogenic cell death), PD-1 inhibitors (which restore T-cell function), and chemotherapy (which enhances antigen exposure), have each demonstrated therapeutic potential. The rational and scientific combination of these three modalities is expected to open a promising comprehensive treatment pathway for patients with advanced non-small cell lung cancer. During his presentation, Director Liu systematically elaborated on the mechanism of action, clinical efficacy, and safety of this combined strategy through detailed clinical research data and clear comparative charts. His solid content and forward-looking perspective attracted widespread attention and lively discussion among attending experts and scholars.
This presentation not only showcased Guangzhou Fuda Cancer Hospital’s active exploration and clinical achievements in the field of comprehensive lung cancer treatment, but also reflected the growing academic influence of Chinese oncology on the international stage. The hospital will continue to uphold an innovative and open approach, promoting the integrated development of interventional technologies and comprehensive cancer treatment, and bringing new hope to more patients.